Mohammad Azab - Net Worth and Insider Trading

Mohammad Azab Net Worth

The estimated net worth of Mohammad Azab is at least $2 Million dollars as of 2024-04-27. Mohammad Azab is the Director of Xenon Pharmaceuticals Inc and owns about 57,561 shares of Xenon Pharmaceuticals Inc (XENE) stock worth over $2 Million. Mohammad Azab is also the Director of Durect Corp and owns about 3,000 shares of Durect Corp (DRRX) stock worth over $2,794. Details can be seen in Mohammad Azab's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mohammad Azab has not made any transactions after 2022-05-17 and currently still holds the listed stock(s).

Transaction Summary of Mohammad Azab

To

Mohammad Azab Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mohammad Azab owns 4 companies in total, including Xenon Pharmaceuticals Inc (XENE) , Novelion Therapeutics Inc (NVLNF) , and Durect Corp (DRRX) among others .

Click here to see the complete history of Mohammad Azab’s form 4 insider trades.

Insider Ownership Summary of Mohammad Azab

Ticker Comapny Transaction Date Type of Owner
XENE Xenon Pharmaceuticals Inc 2019-09-13 director
NVLNF Novelion Therapeutics Inc 2005-05-24 Exec VP-R&D & CMO
DRRX Durect Corp 2022-05-17 director
LSTA Lisata Therapeutics Inc 2022-09-15 director

Mohammad Azab Latest Holdings Summary

Mohammad Azab currently owns a total of 2 stocks. Among these stocks, Mohammad Azab owns 57,561 shares of Xenon Pharmaceuticals Inc (XENE) as of September 13, 2019, with a value of $2 Million and a weighting of 99.88%. Mohammad Azab also owns 3,000 shares of Durect Corp (DRRX) as of May 17, 2022, with a value of $2,794 and a weighting of 0.12%.

Latest Holdings of Mohammad Azab

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
XENE Xenon Pharmaceuticals Inc 2019-09-13 57,561 40.50 2,331,221
DRRX Durect Corp 2022-05-17 3,000 0.93 2,794

Holding Weightings of Mohammad Azab


Mohammad Azab Form 4 Trading Tracker

According to the SEC Form 4 filings, Mohammad Azab has made a total of 1 transactions in Xenon Pharmaceuticals Inc (XENE) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Xenon Pharmaceuticals Inc is the sale of 23 shares on September 13, 2019, which brought Mohammad Azab around $214.

According to the SEC Form 4 filings, Mohammad Azab has made a total of 1 transactions in Durect Corp (DRRX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Durect Corp is the acquisition of 3,000 shares on May 17, 2022, which cost Mohammad Azab around $12,300.

Insider Trading History of Mohammad Azab

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mohammad Azab Trading Performance

GuruFocus tracks the stock performance after each of Mohammad Azab's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mohammad Azab is 35.09%. GuruFocus also compares Mohammad Azab's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mohammad Azab within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mohammad Azab's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mohammad Azab

Average Return

235.7%

Average return per transaction

Outperforming Transactions

100%

4 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 11.32 35.09 75.98 235.7 84.19 62.78
Relative Return to S&P 500(%) 11.23 28.94 70.85 225.01 74.57 51.63

Mohammad Azab Ownership Network

Ownership Network List of Mohammad Azab

No Data

Ownership Network Relation of Mohammad Azab


Mohammad Azab Owned Company Details

What does Xenon Pharmaceuticals Inc do?

Who are the key executives at Xenon Pharmaceuticals Inc?

Mohammad Azab is the director of Xenon Pharmaceuticals Inc. Other key executives at Xenon Pharmaceuticals Inc include SVP Bus. & Corp. Development Sherrington Robin , director & PRESIDENT & CEO Ian Mortimer , and Chief Medical Officer Christopher John Kenney .

Xenon Pharmaceuticals Inc (XENE) Insider Trades Summary

Over the past 18 months, Mohammad Azab made no insider transaction in Xenon Pharmaceuticals Inc (XENE). Other recent insider transactions involving Xenon Pharmaceuticals Inc (XENE) include a net sale of 30,570 shares made by Gary Patou , a net sale of 150,477 shares made by Simon N. Pimstone , and a net sale of 31,655 shares made by Ian Mortimer .

In summary, during the past 3 months, insiders sold 22,229 shares of Xenon Pharmaceuticals Inc (XENE) in total and bought 0 shares, with a net sale of 22,229 shares. During the past 18 months, 260,631 shares of Xenon Pharmaceuticals Inc (XENE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 260,631 shares.

Xenon Pharmaceuticals Inc (XENE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Xenon Pharmaceuticals Inc Insider Transactions

No Available Data

Mohammad Azab Mailing Address

Above is the net worth, insider trading, and ownership report for Mohammad Azab. You might contact Mohammad Azab via mailing address: C/o Supergen, Inc., 4140 Dublin Blvd., Suite 200, Dublin Ca 94568.

Discussions on Mohammad Azab

No discussions yet.